Resultats globals: 1 registres trobats en 0.03 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
25 p, 1.7 MB Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma / O'Brien, Susan (University of California) ; Hillmen, Peter (St. James University Hospital) ; Coutre, Steven E (Stanford University School of Medicine) ; Barr, Paul M (University of Rochester Cancer Center) ; Fraser, Graeme (McMaster University (Canadà)) ; Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ; Burger, Jan A. (University of Texas MD Anderson Cancer Center) ; Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ; Hess, Georg (Universitats Medizin Mainz) ; Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cramer, Paula (University of Cologne) ; Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ; Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ; Vermeulen, Jessica (Janssen Research & Development) ; Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ; Howes, Angela (Janssen Research & Development) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ; Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ; Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ; Universitat Autònoma de Barcelona
Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. [...]
2018 - 10.1016/j.clml.2018.06.016
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 10 (october 2018) , p. 648-657.e15  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.